

A/Prof Mark Frydenberg

Current Position:

Chairman, Department of Urology, Monash Medical Centre; Associate Professor, Department of Surgery, Monash University; Clinical Director, Centre for Urological Research (CURE), Monash Institute of Medical Research (MIMR), Monash University.

A. UNDERGRADUATE

I entered the University of Melbourne Medical School in 1977 and graduated in 1982 with honours. I was awarded the Upjohn Prize of Clinical Pharmacology and Therapeutics in my final year.

My elective term was spent in surgical intern rotations at the Harbor UCLA Medical Center, Torrance, California, USA (8 weeks) and at the Foothills Hospital, Calgary, Alberta, Canada (8 weeks).

B. POSTGRADUATE

- 1983 Intern, Austin Hospital, Melbourne.
- 1984 Junior Surgical Resident, Austin Hospital, Melbourne.
- 1985 Senior Surgical Resident, Austin Hospital, Melbourne.
- 1986 General Surgery Registrar, Austin Hospital, Melbourne.
- 1987 Urology Fellow, Prince Henry's Hospital, Melbourne.
- 1988 Urology Registrar, The Royal North Shore Hospital, Sydney.
- 1989 Urology Registrar, Royal Prince Alfred Hospital, Sydney. Urology Registrar, The Prince Henry Hospital, Sydney.

C. POST FELLOWSHIP

1991, January – June	Consultant Urologist
	Royal Melbourne Hospital
	Monash Medical Centre, Prince Henry's campus
	Western Hospital
1991, July – July 1992	Urologic Oncology Fellow
	Mayo Clinic, Rochester, Minnesota, USA
1992, September to end 1993	Consultant Urologist, Monash Medical Centre
1992, September – Sept 1997	Consultant Urologist, Royal Melbourne Hospital

1997, September to present

Chairman, Department of Urology, Monash Medical Centre, Victoria, Australia

Clinical Associate Professor, Department of Surgery, Monash University

D. EXTRA QUALIFICATIONS

Fellow of the Royal Australasian College of Surgeons in January 1991.

ECFMG certification July 1988.

Clinical Associate Professor, Department of Surgery , Department of Psychological Medicine and Monash Institute of Medical Research, Monash University,

E. ORGANISATIONS

Member of the Urological Society of Australia and New Zealand .

Member of the Society of Urologic Oncology.

Corresponding member of the American Urological Association.

Member of the European Association of Urology. Member of the Endourology Society.

F. PRIZES

Current Concepts in the Pathogenesis and Management of Urinary Tract Infections. State Section Meeting, Urological Society of Australasia, NSW Section, October 1989, Thredbo, Awarded Prize for the Best Trainee's Presentation.

Androgen and Epidermal Growth Factor Receptor Status in Benign and Malignant Prostatic Disease. Annual Scientific Meeting, Urological Society of Australasia, May 1990, Darwin. Awarded the Keith Kirkland prize for the Best Advanced Trainee's Presentation

Fertility after Radiotherapy for Stage 1 Seminoma. State Section Meeting, Urological Society of Australasia, NSW Section, September 1990, Mudgee. Awarded the Prize for the Best Trainee's Presentation

G. COMMITTEES

Expert reviewer for Journal of Urology , Urology, Journal of Urologic Oncology , Brazilian Journal of Urology and ANZ Journal of Surgery.

Chairman , Urologic Oncology Special Advisory Group , Urological Society of Australia and New Zealand

Board member , Andrology Australia

Management group member , Australian Prostate and Urogenital Cancer Trials Group

Chairman , Urologic Oncology Group , Southern Metropolitan Integrated Cancer Service Member Victorian Co-operative Oncology Group, Urological Study Committee, Cancer Council Victoria

H. PUBLICATIONS

- Frydenberg M, Lawson P. (1988) Penile gangrene: A separate entity to Fournier's syndrome. *Br J Urol* 61 (6) 532-33
- Frydenberg M, Love CJ. (1988) Urethral diverticular calculus formed upon a nylon suture. *Br J Urol* 62 (6) 614
- Frydenberg M, Royal JP, Hoare M (1990) Blunt abdominal aortic trauma. *ANZ J Surg* 60(5) 347-50
- Frydenberg M, Foo TM, Jones AS, Grace J, Hensley WJ, Rogers J, Pearson BS, Raghavan D. (1991) Benign prostatic hyperplasia: video image analysis and its relationship to androgen and epidermal growth factor receptor expression. *J Urol* 146(3): 872-6
- Frydenberg M, Ferguson R, Langdon P, Rogers J, McCarthy S. (1991) Malignant pheochromocytoma of the bladder-active or inactive. *Br J Urol* 67(5) 548-9
- Frydenberg M Eckstein RP, Saalfeld JA, Breslin FH, Alexander JH, Roche J (1991) Renal oncocytomas – an Australian experience. *Br J Urol* 67 (4): 352-7
- Frydenberg M, Malek R. (1993) Human papillomavirus infection and its relationship to carcinoma of the penis. In, *Urology Annual 1993*; 7: 185-198 WW Norton and Co
- Frydenberg M, Oesterling JE (1993) therapeutic options in clinical stage C prostate cancer, In, *Problems in Urology 1993*; 7(2): 166-179 JB Lippincott Co
- Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. (1993) Radical prostatectomy for pathology stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. *Urology* 42(3) 283-91
- Frydenberg M, Malek RS, Zincke H. (1993) Conservative renal surgery for renal cell carcinoma in von Hippel-Lindaus's disease. *J Urol* 149 (3) 461-4
- Cheng WS, Bergstralh EJ, Frydenberg M, Zincke H. (1994) Prostate specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome. *Eur Urol* 25(3): 189-93
- Velagupudi SR, Frydenberg M, Oesterling JE, Bergstralh EJ, Moore SB, Ruckle HC, Zincke H.(1994) Homologous blood transfusion in patients with prostate cancer: no effect on tumour progression or survival. *Urology* 43(6): 821-7
- Frydenberg M, Gunderson L, Hahn G, Fieck J, Zincke H. (1994) Pre-operative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies.
- Frydenberg M (1995) Current status of prostate cancer research. *Cancer Forum* 19(1) 15-18
- Frydenberg M, Oesterling JE. Management of stage C (T3) prostate cancer: non-radiation therapy. In, *Principles and*

practice of genitourinary oncology, JB Lippincott, 1996

Frydenberg, M, Stricker P, Kaye K. (1997) Prostate cancer diagnosis and management. *Lancet* 349(9006): 1681-7

Clarke A, Frydenberg M, Lindsay S, Byron K, Ratnaik S. (1997) The use of the cell saver during radical prostatectomy: RTPCR detection of viable PSA-producing prostate cells prior to reinfusion. *ANZ J Surg* 67(6): 359

Lindsay S, Frydenberg M, Byron K, Ratnaik S. (1997) the effects of prostatic biopsy: PSA RTPCR assessment of prostate cell dispersion into the venous circulation. *ANZ J Surg* (67(6) 361

Frydenberg M, Byron K, Ratnaik S, Lindsay S, Clarke A. (1997) Molecular staging of localized prostate cancer: The utility of prostate-specific antigen reverse transcriptase-polymerase chain reaction (PSA RTPCR) *ANZ J Surg* 67(6): 367

Frydenberg M, Ratnaik S, Byron K, Paiman L. (1997) PSA recurrence following radical prostatectomy: Can prostate specific antigen-reverse transcriptase-polymerase chain reaction (PSA-RT-PCR) differentiate between local and distant sites of relapse. *J Urol* 157(4) A 1254: 321

Frydenberg M. (1998) Radical prostatectomy: what do patients really think of surgery? *Med J Aust*, 168, 477-8

Lavoipierre A, Gunter D, Reisner G, Snow R, Frydenberg M, Royce P, Wheelahan J, Cato A. (1998) Prostate cancer – role of colour Doppler imaging in transrectal ultrasound. *ANZ J Surg*. 68 (6): 436 A

Frydenberg M, Lindsay S, Clarke A, Ratkaik S, Byron K, Paiman L. (1998) The role of PSA-RT-PCR in the molecular staging of localized prostate cancer and biochemical follow-up following radical retropubic prostatectomy. *ANZ J Surg*. 68 (6) 436-7 A

Lavoipierre A, Lavoipierre G, Gunter D, Reisner G, Snow R, Frydenberg M, Royce P.(1998) Value of echo enhancers in prostate cancer detection by transrectal ultrasound: a pilot study. *ANZ J Surg* (68) (6) 442 A

Frydenberg M, Duchesne G, Stricker P. (1998). Management of localized prostate cancer: state of the art. *Med J Aust*. 169:11-2

Lavoipierre A, Snow R, Frydenberg M, Gunter D, Reisner G, Royce P, Lavoipierre G. (1998) Prostate cancer: role of color Doppler imaging in transrectal sonography. *AJR* 171(1), 205-10

Golovsky D, Bary P, Antuono MD, Frydenberg M, Heathcote P, Kay K, Monsour M, Rogers J, Stapleton A, Stricker P, Verney M. (1999) The effect of percent free prostate-specific antigen (PSA) in the use of prostatic biopsies: An Australasian multi-centre study. *ANZ J Surg* 69(6) A107

Hii W, Gardiner RA, Frydenberg M, Byron K, Clements J, Nicol D. (1999) VEGF Expression in prostate tissue. *ANZ J Surg* 69(6) A112

Wheelahan J, Bolton D, Frydenberg M, Giles G, Mameghan H, Millar J, Syme J, Thursfield V.(1999) The management of prostate cancer in Victoria – 1993. *ANZ J Surg* 69:A120

Frydenberg M, Beilin J, Favaloro J, Byron K, Zajac J, Cleeve L, Harewood L. (1999) Androgen receptor gene CAG repeat polymorphism in prostate cancer. *ANZ J Surg* 69:A123

Frydenberg M, Giles GG, Mameghan H, Thursfield VJ, Millar J, Wheelahan JB, Bolton DM, Syme RR (2000) Prostate

cancer in Victoria in 1993: patterns of reported management. *Med J Aust* 172(6) 270-4

Frydenberg M. (2000) Role of Nephron-sparing surgery in renal cell carcinoma. *ANZ J Surg*, 70: A159

Frydenberg M, Alvarez J, Goldblatt J, McMillan J. (2000) Management of renal cell carcinoma involving the inferior vena cava and right atrium: the role of cardiopulmonary bypass and deep hypothermic arrest. *ANZ J Surg* 70:A160

Jarred RA, Thurn MJ, Frydenberg M, Risbridger GP. (2000) Androgen induced prostate development is inhibited by a synthetically derived isoflavone; NV06. *ANZ J Surg* 70:A164

Risbridger GP, Wang H, Frydenberg M, Cunha GR (2001) Metaplastic effects of estrogen on prostate epithelium: proliferation of cells with basal cell phenotype. *Endocrinology* (142): 2443-2450

Salminen, E, Hogg A, Binns D, Frydenberg M, Hicks R (2001) (18F) Fluorodeoxyglucose positron emissions tomography (SDG-PET) in the management of prostate cancer. Abstract 33. *Scandinavian Journal of Urology and Nephrology*. 35 Sup 208, p25-26.

Schmitt JF, Millar DS, Pedersen JS, Clark SL, Venter DJ, Frydenberg M, Molloy PL and Risbridger GP. 2002. Hypermethylation of the inhibin α -subunit gene in prostate carcinoma. *Molecular Endocrinology* 16 (2) 213-220

McLachlan RI, O'Donnell L, Stanton PG, Balourdos G, Frydenberg M, de Kretser DM, Robertson DM (2002). Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. *JCEM* 87 (2): 546-556

Livingston PM, Cohen P, Borland R, Frydenberg M, Raeding D, Clarke V, Hill D, 2002. Knowledge, attitudes and experience associated with testing for prostate cancer: a comparison between male doctors and men in the community. *ANZ Journal of Internal Medicine*, 32:215-223, 2002

Schmitt J, Dowling C, Millar D, Clark S, Pedersen J, Venter D, Molloy P, Mellor S, Frydenberg M, Risbridger GP. 2001. Evidence for inhibin- α as a tumour suppressor in prostate cancer.

Duchesne G, Frydenberg M, Dowling C, Turner S, Woo H, Joseph D, Gogna K, Roberts S, Neerhut G (2002) Post-prostatectomy radiotherapy: outcome, morbidity and prognostic factors *ANZ Journal of Surgery* 72 (6): A135 Abstract 39

Frydenberg M, Toner G, Thursfield VJ, Giles GG (2002) The management of muscle invasive bladder cancer in Victoria, Australia: 1990-1995. *IJCC* S13, 114, Abstract 0139

Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. *Cancer Epidemiol Biomarkers Prev*. 2002 Dec; 11(12): 1689-96

Duchesne GM, Dowling C, Frydenberg M, Joseph D, Gogna NK, Neerhut G, Roberts S, Tai KH, Turner S and Woo H. Outcome, morbidity and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. *Urology* 2003; 61: 179-183

Toner GC, Frydenberg M. Poor prognosis germ-cell tumours: an unresolved challenge. *Seminars in Urologic Oncology*, Volume 20, Number 4 (November), 2002: 251-261

Dunsmuir WD, McFarlane J, Tan A, Dowling C, Downie J, Kourambas J, Donnellan S, Redgrave N, Fletcher R, Frydenberg M and Love C. (2003) Gyros a bipolar electrovaporization versus transurethral resection of the prostate: a

randomized prospective single-blind with 1-year follow-up. Prostate Cancer & Prostate Diseases 6: 182-6

Frydenberg, M. (2004) Testis cancer; assessment and management. Medicine Today August 2004, 5: 8 pp39-44

Frydenberg M, Millar JL, Toner G, Bolton D, Syme R, Thursfield VJ, Giles GG and Urology Study Committee of the Victorian Co-operative Oncology Group, Cancer Council of Victoria. Management of superficial bladder cancer in Victoria: 1990 and 1995. ANZ J. Surg. 2005, 75: Pages 270-274,

Jeremy L. Millar, Mark Frydenberg, Guy Toner, Rodney Syme, Vicky Thursfield and Graham G. Giles, For The Urology Study Committee Of The Victorian Co-Operative Oncology Group: ANZ J. Surg. 2006; 76: 113-119

G. Risbridger, M. Frydenberg, P. Cowin, R. Taylor, G. Cunha, M. Pera, A. Trounson and J. Pedersen. Development and maturation of human prostate from embryonic stem cells in vivo. ANZ J Surgery. BJU Int: Vol 97, Supplement 1, p9, 2006

Newton,F. , Burney,S., Frydenberg, M., Millar, J., and Ng, K Assessing mood and general health-related quality of life among men treated in Australia for localised prostate cancer. International Journal of Urology 14 (4):311-316, 2007

Frydenberg, M., Lawrentschuk , N., Chapter 9, Benign Prostatic Hypertrophy in Endotext ; www.endotext.com

Wooten , A.C., Burney,S., Faroudi,F., Frydenberg,M., Coleman,G., Ng,K. Psychological adjustment of survivors of localized prostate cancer: investigating the role of dyadic adjustment,cognitive appraisal and coping style ; Psycho-Oncology 16(11):994-1002 , 2007

Wooten,A.C., Burney,S.,Frydenberg,M.,Faroudi,F.,Ng,K.,Coleman,G., Long erm experience of residual symptoms following treatment for localized prostate cancer: An Australian sample : Asia Pacific Journal of Clinical Oncology : 3,189-196, 2007

Wooten,A., Burney,S., Frydenberg,M., Coleman,G., Ng ,K.,Faroudi,F. Long term quality of life of partners of patients treated for localized prostate cancer : Investigating the variables involved in psychological adjustment ; Submitted to Quality of Life Research Journal ,2007

Newton,F.J., Burney , S., Millar, J.L., Frydenberg, M., Ng, K.T., Disease specific quality of life among localized prostate cancer patients : An Australian perspective BJU Int 97:1179-1198,2006

Frydenberg M., Re: The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy; International Braz J Urol 33(4) 562-563,2007

I. INVITED SPEAKER

Urological Society of Australia and New Zealand State Meetings of :

Tasmania
South Australia
Queensland
New Zealand
NSW

Urological Society of Australia and New Zealand National Meetings :

1994
2007
2008 Convenor of 2009 meeting

World Urologic Oncology Federation , Societe Internationale D'Urologie , Paris ,2007
Clinical Oncological Society of Australia , Adelaide 2007
Uroscience meeting , Noosa, 2007

J. RECENT GRANTS

A phase 3 trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy :
Cancer Council Victoria , 2007, \$296,000 over 3 years

A phase 3 trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy :
Cancer Council NSW , 2007 , \$177,000 over 3 years

Australian Prostate Cancer Bioresource ; NHMRC ,2005-2009 , \$420,000/annum

Psycho-oncology research Grant , Cabrini Health , 2008-2009, \$80,000 over 2 years

Systematic collection and retrieval of data and tissue in patients with renal cell carcinoma VCA , 2007, \$220,910, over
2 years

Australian Prostate and Urogenital Cancers Trials Group ; Cancer Australia , \$200,000, 2007